Breaking News

A rare pressure campaign to confirm Califf at FDA; early study suggests stimulation could jolt spinal cord back to life

  

 

Daily Recap

STAT+: In a bid to save Biden's FDA pick, doctors and public health groups are mounting a rare pressure campaign

By Nicholas Florko and Rachel Cohrs

Andrew Harnik/AP

Some of the nation’s most influential doctors and public health groups are orchestrating a mad-dash effort to confirm Robert Califf.

Read More

Walking again after paralysis: Early study suggests stimulation could jolt spinal cord back to life

By Isabella Cueto

Courtesy Alain Herzog

Precisely stimulating nerves in the spinal cord could quickly restore walking, swimming, and cycling after paralysis, a new study suggests.

Read More

STAT+: In a victory for medical journals, Pacira loses a libel lawsuit over 'faulty scientific research' allegations

By Ed Silverman

Adobe

A federal judge has dismissed a libel lawsuit brought by Pacira Biosciences against a medical journal that published research on its drug.

Read More

Opinion: The Supreme Court is partly to blame for the Covid-19 test kit shortage

By Paul R. Michel

FREDERIC J. BROWN/AFP via Getty Images

The 2012 Supreme Court decision known as Mayo v. Prometheus effectively blocked patent protections for diagnostic tests and procedures.

Read More

STAT+: The quest for the small molecule holy grail with Merck's head of R&D

By Meg Tirrell and Adam Feuerstein and Damian Garde

Mel Evans/AP

Merck scientists are trying to solve how to design a more convenient pill that can lower cholesterol by also blocking PCSK9.

Read More

Opinion: STAT+: Manufacturing at the edge: smaller, localized, and agile factories will be key to biopharma drug production

By Jose-Carlos Gutiérrez-Ramos

Adobe

Biopharma must take a lesson from "edge computing" and move toward "edge manufacturing," bringing it closer to the patient.

Read More

Monday, February 7, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments